We further investigated if p37 peptide which inhibits HER2 heterodimerization, has a mechanism of tumor cell growth-inhibitory action that is complementary to that of trastuzumab which has been shown to preferentially block HER2 homodimer [17]. This evidence concerns the gene ERBB2 and neoplasm.